Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.

PURPOSE To estimate the cost-effectiveness from a French payer perspective of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) alone compared with CHOP plus rituximab (R-CHOP) for treatment of patients with diffuse large B-cell lymphoma. METHODS Mean patient survival, days of hospitalization, and chemotherapy costs during treatment were… CONTINUE READING